JPWO2022102737A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2022102737A5
JPWO2022102737A5 JP2022562195A JP2022562195A JPWO2022102737A5 JP WO2022102737 A5 JPWO2022102737 A5 JP WO2022102737A5 JP 2022562195 A JP2022562195 A JP 2022562195A JP 2022562195 A JP2022562195 A JP 2022562195A JP WO2022102737 A5 JPWO2022102737 A5 JP WO2022102737A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
administration
edaravone
time interval
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022562195A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2022102737A1 (cg-RX-API-DMAC7.html
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2021/041673 external-priority patent/WO2022102737A1/ja
Publication of JPWO2022102737A1 publication Critical patent/JPWO2022102737A1/ja
Publication of JPWO2022102737A5 publication Critical patent/JPWO2022102737A5/ja
Priority to JP2025002313A priority Critical patent/JP2025061070A/ja
Pending legal-status Critical Current

Links

JP2022562195A 2020-11-12 2021-11-12 Pending JPWO2022102737A1 (cg-RX-API-DMAC7.html)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025002313A JP2025061070A (ja) 2020-11-12 2025-01-07 エダラボン経口投与用医薬組成物およびその投与方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2020188514 2020-11-12
PCT/JP2021/041673 WO2022102737A1 (ja) 2020-11-12 2021-11-12 エダラボン経口投与用医薬組成物およびその投与方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025002313A Division JP2025061070A (ja) 2020-11-12 2025-01-07 エダラボン経口投与用医薬組成物およびその投与方法

Publications (2)

Publication Number Publication Date
JPWO2022102737A1 JPWO2022102737A1 (cg-RX-API-DMAC7.html) 2022-05-19
JPWO2022102737A5 true JPWO2022102737A5 (cg-RX-API-DMAC7.html) 2023-07-12

Family

ID=81602356

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022562195A Pending JPWO2022102737A1 (cg-RX-API-DMAC7.html) 2020-11-12 2021-11-12
JP2025002313A Pending JP2025061070A (ja) 2020-11-12 2025-01-07 エダラボン経口投与用医薬組成物およびその投与方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025002313A Pending JP2025061070A (ja) 2020-11-12 2025-01-07 エダラボン経口投与用医薬組成物およびその投与方法

Country Status (11)

Country Link
US (2) US11911366B2 (cg-RX-API-DMAC7.html)
EP (1) EP4245303A4 (cg-RX-API-DMAC7.html)
JP (2) JPWO2022102737A1 (cg-RX-API-DMAC7.html)
KR (1) KR20230098267A (cg-RX-API-DMAC7.html)
CN (1) CN116761601A (cg-RX-API-DMAC7.html)
AR (1) AR124062A1 (cg-RX-API-DMAC7.html)
AU (2) AU2021380319B2 (cg-RX-API-DMAC7.html)
CA (1) CA3198014A1 (cg-RX-API-DMAC7.html)
IL (1) IL302533A (cg-RX-API-DMAC7.html)
TW (1) TW202228678A (cg-RX-API-DMAC7.html)
WO (1) WO2022102737A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024036261A2 (en) * 2022-08-10 2024-02-15 Kpr U.S., Llc Occlusion detection system and method for a flow control apparatus
EP4559463A1 (en) * 2023-11-23 2025-05-28 Ferrer Internacional, S.A. Edaravone or its salts for use in the treatment of oxidative stress-mediated neurodegenerative disorders

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61263917A (ja) 1985-05-20 1986-11-21 Mitsubishi Yuka Yakuhin Kk 脳機能正常化剤
JPH0531523A (ja) 1991-07-26 1993-02-09 Aichi Steel Works Ltd ロ−ラ回転数・間隙測定可能な圧延機用ロ−ラガイド装置
ES2248144T3 (es) 2000-10-24 2006-03-16 Mitsubishi Pharma Corporation Medicamentos para tratar la esclerosis lateral amiotrofica (ela).
CN109125261B (zh) * 2016-03-16 2021-11-30 苏州澳宗生物科技有限公司 依达拉奉剂型
EP3785703A1 (en) * 2017-01-17 2021-03-03 Treeway TW001 B.V. Treatment comprising oral or gastric administration of edaravone
CN110381923A (zh) * 2017-01-17 2019-10-25 萃微Tw001公司 包括肠内施用依达拉奉的医学治疗
BR112021008197A2 (pt) 2018-11-02 2021-08-03 Mitsubishi Tanabe Pharma Corporation suspensão de edaravone para administração oral
JP7012792B2 (ja) 2020-08-06 2022-01-28 株式会社 ディー・エヌ・エー 動画を配信するためのシステム、方法、及びプログラム
US12194025B2 (en) 2020-11-12 2025-01-14 Mitsubishi Tanabe Pharma Corporation Pharmaceutical composition for oral administration of edaravone and method of administering same

Similar Documents

Publication Publication Date Title
JP2023515472A5 (cg-RX-API-DMAC7.html)
JP2021504420A5 (cg-RX-API-DMAC7.html)
JP2010509326A5 (cg-RX-API-DMAC7.html)
JP2020527583A5 (cg-RX-API-DMAC7.html)
JP5232404B2 (ja) 有胞子性乳酸菌含有抗感冒ウイルス又は抗インフルエンザウイルス用組成物
US5545668A (en) Oral glutamine to reduce stomatitis
TWI455723B (zh) 納曲酮及安非他酮於治療超重或肥胖病患之用途
WO2004058243A1 (ja) 肝癌発生・進展抑制剤
AU2012235869A1 (en) Compositions for the treatment of neurologic disorders
JP2010511039A5 (cg-RX-API-DMAC7.html)
JP2019218379A5 (cg-RX-API-DMAC7.html)
JPS59112948A (ja) コレステロ−ルレベル低下剤
JP2002322088A (ja) 口腔貼付用製剤
ES2763437T3 (es) Composición para el tratamiento de la esterilidad
US2438106A (en) Peroral penicillin compositions
JP2019531286A5 (cg-RX-API-DMAC7.html)
JP2024531799A5 (cg-RX-API-DMAC7.html)
JP2021512086A5 (cg-RX-API-DMAC7.html)
WO2006001492A1 (ja) 栄養組成物および消化管機能低下予防・改善用組成物
CN103919774A (zh) 去亚甲基小檗碱在制备降血脂药物中的应用
TW415843B (en) Anti-cancer pharmaceutical compositions comprising a diaminotrifluoromethylpyridine derivatives or the pharmaceutically acceptable salts thereof
US12514842B2 (en) Use of a benzoate containing composition to treat neurodegenerative disorders
JP5555401B2 (ja) C型肝炎ウイルス陽性ヒト肝硬変患者用肝癌発生・進展抑制剤
CN109999044B (zh) 一种含有醉茄素a的组合物及其应用
JP2023533472A5 (cg-RX-API-DMAC7.html)